Biote announcesTerry Weber retires Bret Christensen named CEO
(BTMD) announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company’s Board of Directors, ...
DNA Testing Market Increasing Size, Demand, Growth Rate, And Forecast 2033 - Emergen Research
Emergen Research Logo The DNA Testing market is expected to grow from an estimated USD 12.51 billion in 2024 to USD 81.82 billion in 2033, ...
Myriad Genetics (NASDAQ:MYGN) Given New $14.00 Price Target at Piper Sandler
Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its target price cut by analysts at Piper Sandler from $24.00 to $14.00 in a research note issued on Thursday,Benzinga reports. The brokerage ...
Consumer Genomics Market Size to Hit USD 10.8 Billion by 2032, Growing at a 24.6% CAGR - SNS Insider
Consumer Genomics Market growth is driven by rapid advancements in genetic testing technologies, declining sequencing costs, and increasing consumer awarenessPune, Jan. 31, 2025 (GLOBE NEWSWIRE) -- ...
Nature5d
Structural variation in the human genome
Structural variants in the human genome include cytogenetically detectable and submicroscopic deletions, duplications, large-scale copy-number variants, inversions and translocations. The ability ...
Zacks.com on MSN5d
Is QIAGEN Stock an Apt Pick for Your Portfolio Right Now?
QIAGEN N.V.’s QGEN long-term business strategy focuses on forming partnerships for the development, commercialization, marketing and distribution of existing and future products. The company sees ...
Myriad Genetics price target lowered to $14 from $24 at Piper Sandler
Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on ...
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
Opening plenary session features latest fetal fraction amplification researchSALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) - ...
The Bakersfield Californian6d
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at ...